Luminex's Q3 Revenues Rise 35 Percent on Assay Growth | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Luminex's third-quarter revenues rose 35 percent year over year with assay sales climbing 70 percent, the company reported after the close of the market on Tuesday.

The company said that total revenues in the quarter came in at $45.6 million for the three months ended Sept. 30, compared to $33.9 million a year ago, outpacing Wall Street estimates of $43.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.